Skip to main content Skip to section navigation Skip to footer
Careers News & Media Contact
OPKO Health, Inc. OPKO Health, Inc.
  • Therapies
    • Overview
    • Ngenla
    • Rayaldee
  • Research
    • Overview
    • Pipeline
    • Publications
    • Scientific Presentations
  • Diagnostics
  • Company
    • Overview
    • Leadership
    • Locations
  • Partnerships
  • Investors
    • Overview
    • News / Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • News & Media
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Proxy Materials
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Form 8937
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Feb 10, 2009 12:15pm EST

OPKO To Present Data on Next Generation Anti-Angiogenic VEGF165b-Sparing siRNA at Association for Research and Vision in Ophthalmology (ARVO 2009) Meeting

Jan 23, 2009 9:13am EST

OPKO Receives FDA 510(k) Clearance for Spectral OCT SLO Combination Imaging System

Jan 22, 2009 1:49pm EST

OPKO Health Initiates Clinical Trial of the Aquashunt(TM) to Treat Glaucoma

Dec 04, 2008 9:16am EST

OPKO Health Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD

Oct 02, 2008 1:12pm EDT

OPKO Acquires Worldwide Ophthalmic Rights to Teva's Budesonide for Inflammatory and Allergic Ocular Conditions

Sep 17, 2008 9:00am EDT

OPKO Health to Present at UBS 2008 Global Life Sciences Conference

Jun 17, 2008 9:35am EDT

OPKO Health, Inc. Set to Join Russell 3000 Index

Jun 12, 2008 8:00am EDT

OPKO Acquires Rights to Novel Phase II Agent to Treat Viral Conjunctivitis

Jun 03, 2008 11:51am EDT

Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye

May 07, 2008 7:45am EDT

OPKO Health Acquires Company Developing Novel Glaucoma Therapy

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • Page 51
  • Page 52
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, FL 33137


T: 305-575-4100
contact@opko.com

©2025 OPKO Health, Inc. All Rights Reserved.
Privacy Policy Governance Terms of use Sitemap